Login to Your Account

Dendreon Sells Victrelis Royalty; Provenge Filing Ahead

By Jennifer Boggs
Managing Editor

Wednesday, December 7, 2011
Seattle-based Dendreon Corp., which made headlines throughout 2011 due to slower-than-expected sales of prostate cancer vaccine Provenge (sipuleucel-T), agreed to sell its royalty interest related to hepatitis C virus (HCV) drug Victrelis (boceprevir) for $125 million in cash.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription